These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 22191466)
1. Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio. Zoller H; Schloegl A; Schroecksnadel S; Vogel W; Fuchs D J Interferon Cytokine Res; 2012 May; 32(5):216-20. PubMed ID: 22191466 [TBL] [Abstract][Full Text] [Related]
2. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Zangerle R; Kurz K; Neurauter G; Kitchen M; Sarcletti M; Fuchs D Brain Behav Immun; 2010 Mar; 24(3):403-8. PubMed ID: 19925861 [TBL] [Abstract][Full Text] [Related]
3. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Aziz H; Raza A; Waheed Y; Gill U; Gill ML Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873 [TBL] [Abstract][Full Text] [Related]
4. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854 [TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI). Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G; J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183 [TBL] [Abstract][Full Text] [Related]
6. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients. Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J; J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185 [TBL] [Abstract][Full Text] [Related]
8. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan. Gill U; Aziz H; Gill ML Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656 [TBL] [Abstract][Full Text] [Related]
9. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes? Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644 [TBL] [Abstract][Full Text] [Related]
10. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484 [TBL] [Abstract][Full Text] [Related]
12. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221 [TBL] [Abstract][Full Text] [Related]
13. Psychiatric side effects and fluctuations in serotonergic parameters in the treatment of chronic hepatitis C infection. Bezemer G; Van Gool AR; Fekkes D; Vrolijk JM; Hansen BE; Janssen HL; de Knegt RJ Neuropsychobiology; 2012; 65(3):126-32. PubMed ID: 22378062 [TBL] [Abstract][Full Text] [Related]
14. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487 [TBL] [Abstract][Full Text] [Related]
17. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053 [TBL] [Abstract][Full Text] [Related]
18. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study. Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B; Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715 [TBL] [Abstract][Full Text] [Related]
19. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P; J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]